BIrmingham, Alabama (PRWEB) February 28, 2013
The law firm of Cory Watson Crowder & DeGaris has reached an agreement with Pfizer to settle all of the firm’s clients’ claims involving the smoking cessation drug Chantix, according to Plaintiffs' attoney Ernest Cory. “We have reached a resolution of the litigation on behalf of all of the Chantix clients of Cory Watson Crowder & DeGaris, subject to the approval of our clients,” said Ernest Cory who represents two hundred fifty four Chantix clients in twenty eight states. The terms of the settlement are confidential, according to Cory who says he is pleased that his clients will be able to put the litigation behind them.
The litigation, In Re: Chantix (Varenicline) Products Liability Litigation, MDL No. 2092, is consolidated before Judge Inge Johnson in Federal Court in the Northern District of Alabama, (Florence, Alabama), where more than 2700 plaintiffs have filed lawsuits against Pfizer. In 2010 Judge Johnson appointed Mr. Cory to serve as Plaintiffs’ Lead Counsel in the litigation. “From the beginning, our firm has taken this litigation very seriously and I will continue to serve as Plaintiffs’ Lead Counsel until all remaining plaintiffs have resolved their cases and there is no longer a need for an MDL,” said Cory. Attorneys Kristian Rasmussen, Elizabeth Chambers and Stephen Hunt, all of Cory Watson Crowder & DeGaris, also played key roles in the litigation.
Cory Watson Crowder and DeGaris is a Birmingham, Alabama law firm recognized nationally for its practice areas of complex litigation including class actions, pharmaceutical drug litigation, defective medical device litigation, products liability litigation, business and securities litigation, environmental litigation, multidistrict litigation and mass torts. The law firm has an extensive practice in individual personal injury and wrongful death cases.